New combo offers gentler option for rare leukemia
NCT ID NCT05388123
First seen May 12, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This study tested a combination of two drugs, vemurafenib (taken by mouth) and rituximab (given through a vein), for people with hairy cell leukemia. The goal was to see if this treatment works as well as or better than standard chemotherapy, but with fewer side effects. The study included 15 adults who either had not been treated before or whose cancer had returned after prior therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Scripps Cancer Center
La Jolla, California, 92037, United States
Conditions
Explore the condition pages connected to this study.